Achieving the launch of the world's first Ras-targeted nucleic acid medicine
e-NA Biotec Inc. is a drug discovery bio-venture company originating from Gifu University. Based on the research results of professors both, Dr. Kitade and Dr. Akao at Gifu University for many years, we aims to bring microRNA medicine (nucleic acid medicine) to the market and patient.
Our company was established on January 11, 2018 under program for creating start-ups from advanced research and technology (START) supported by the National Institute of Science and Technology Agency (JST) in japan.
In the field of nucleic acid medicine, where exponential design exists, we are continuing research and development of the world's first Ras-targeted microRNA medicine using highly chemically modified microRNAs discovered by utilizing our know-how.
e-NA BIOTEC INC.
MicroRNAs are one of the most important bio-molecules and play a major role in maintaining homeostasis in our bodies.
Therefore, it is often thought that distortions in its expression in the cell and a significant change in the surrounding environment can cause diseases, especially cancer.
We are focusing on microRNAs associated with these diseases in our drug discovery and development.
MISSION
Our mission is to advance microRNA drug candidates (seeds) into preclinical and clinical trials as quickly as possible and to make therapeutics available to patients in unmet medical needs worldwide.
Through our business, we believe that we can improve the quality of life of patients and contribute to society by creating a new future based on science, based on the knowledge we have gained through our long-standing research on nucleic acids.
SCIENCE
We are engaged in microRNA drug discovery and development, sales of patented technologies based on nucleic acid modification technologies, and technical support and consulting on nucleic acid design methods.
Currently, we have development projects underway for two types of cancer. We are also engaged in the search for disease-related microRNAs and research and development related to nucleic acid medicine.
PARTNERING
Partnering (alliances, licensing, and other support) is critical to our mission and vision.
Please feel free to contact us if you are interested in our drug discovery projects and nucleic acid modification technology, which is our specialty. At any time submit your inquiries via our contact form.